Under development Stay tuned.

Feline Leukemia Virus (FeLV), a member of the subfamily of retroviral tumor-causing RNA viruses, contains single-stranded RNA that is transcribed by the action of reverse transcriptase into DNA, a provirus that integrates into the cellular genome of cats.

Globally about 5% of cats are infected with FeLV, and in some countries up to 20%.

The consequences of FeLV infection depend on the age and immune status of the cat, the concentration of the virus, the pathogenicity of the virus and the stress of the infection.

Young cats have the highest susceptibility to FeLV and can gradually gain resistance to the virus as they mature, but more than 50% of poorly resistant cats will still develop disease after infection with the virus.

FeLV is clinical signs vary widely, but often include:

• Dyspnea
• Lethargy
• Anorexia
• Weight loss
• Fever
• Gingivitis/stomatitis and abscesses that are difficult to heal.

There is no specific treatment for this disease and death is almost inevitable once the disease develops.

According to American scientists, the human anti-AIDS drug raltegravir has shown good inhibitory effect on FeLV in vitro.

Based on this finding, we have conducted an in-depth study of MT-5829, a novel long-acting integrase inhibitor designed to effectively inhibit FeLV replication in vivo by inhibiting FeLV integrase without harming normal cells, and therefore has high selectivity and low toxicity.

Based on preliminary data, MT-5829 has largely reduced the viral titer of FeLV and improved the quality of life of affected cats. The next step will be to recruit more FeLV-infected cats for a double-blind placebo-controlled trial.